Nelistotug (immunoglobulin G1-kappa, anti-[Homo sapiens CD96 (T cell activation increased late expression, TACTILE, T-cell surface protein tactile)], Homo sapiens monoclonal antibody)
Neoplasms
GlaxoSmithKlinemonoclonal_antibodyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 65/ 100
Competitive context
927 Active assets in the Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi | Phase 4 | BB |
Glycopyrrolate Medical College of Wisconsin | Phase 4 | BB |
Bxcl501 Medical College of Wisconsin | Phase 4 | BB |
Relatlimab Bristol-Myers Squibb | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Nelistotug (immunoglobulin G1-kappa, anti-[Homo sapiens CD96 (T cell activation increased late expression, TACTILE, T-cell surface protein tactile)], Homo sapiens monoclonal antibody) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →